|
|
|
| Effect of the vascular endothelial growth factor level in peripheral blood of patients with advanced ovarian cancer after neoadjuvant chemotherapy treatment for predicting their tumor reduction satisfaction |
| Shanxi Fenyang Hospital，Fenyang, Shanxi Province, 032200 |
|
|
|
|
Abstract To investigate the clinical value of the vascular endothelial growth factor(VEGF) level in peripheral blood of patients with advanced ovarian cancer after neoadjuvant chemotherapy treatment(NACT) for predicting their tumor reduction satisfaction. Methods: 110 patients with advanced ovarian cancer who had been treated with neoadjuvant chemotherapy from January 2017 to March 2018 were collected. All patients had received 2 courses of neoadjuvant chemotherapy, mainly platinum drugs, and then given cytoreductive surgery and 20 days chemotherapy for least 6 courses after surgery. All patients were divided into group A1(patients with tumor reduction satisfaction) and A2(patients without tumor reduction satisfaction) based on the size of residual tumor lesions after surgery, the patients were divided into group B1(patients with VEGF level ≤151 pg/ml) and group B2(patients with VEGF level＞51 pg/ml) based on the preoperative VEGF level in peripheral blood of the patients, and the patients were divided into group C1(patients with the percentage decrease of VEGF level ≤82%) and group C2(patients with the percentage decrease of VEGF level＞82%) based on the percentage of VEGF level in peripheral blood decrease after surgery. Results: The preoperative VEGF level in peripheral blood(199.96±15.43 pg/ml) of the patients in group A2 was significantly higher than that(145.78±15.37 pg/ml) of the patients in group A1, and the percentage of decrease of the VEGF level(79.98±5.17%) in peripheral blood of the patients in group A2 was significantly lower than that(84.45±5.49%) of the patients in group A1. The satisfaction rate of tumor reduction(97.4%) of the patients in group B1 was significantly higher than that(54.5%) of the patients in group B2, and the satisfaction rate of tumor reduction(95.5%) of the patients in group C2 was significantly higher than that(38.1%) of the patients in group C1(all P<0.05). The influencing factors of the tumor reduction satisfaction of the patients with advanced ovarian cancer were the high preoperative VEGF level and the low postoperative percentage of the VEGF level decrease(all P<0.05). These patients were followed up for at least 5 years, 35 cases survived and 65 cases died, with a mortality rate of 59.1%. The cause of death of all the patients was the ovarian cancer recurrence. The median survival time of the patients in group B1(>60 months) was significantly higher than that(43 months) of the patients in group B2(P<0.05). There was no significant difference in the median survival time(51.8 months vs. 52.3 months) of the patients between group C1 and group C2(P>0.05). Conclusion: The VEGF level in peripheral blood of the patients with advanced ovarian cancer after NACT can be used to predict their satisfactory tumor reduction and 5-year survival situation.
|
|
|
|
|
|
|
|
|
